Global /South Korea /Healthcare /Biotechnology /086060
chevron_leftBack
GeneBioTech Co. ,Ltd logo

GeneBioTech Co. ,Ltd

086060
KRX: 086060 Delayed
4,665KRW -2.4%
3.06 USD
As of 13 June 2026, GeneBioTech Co. ,Ltd has a market cap of $26.41M USD, ranking #35131 globally and #2188 in South Korea. It ranks #3172 in the Healthcare sector, and #612 in the Biotechnology industry.
Global Rank
35131
Country Rank
2188
Sector Rank
3172
Industry Rank
612
Key Stats
Market Cap
$26.41MUSD
40.17B KRW
Enterprise Value
$19.81MUSD
30.23B KRW
Revenue (TTM)
$59.7MUSD
90.79B KRW
EBITDA (TTM)
$3.53MUSD
5.38B KRW
Net Income (TTM)
$2.49MUSD
3.79B KRW
EBITDA Margin
5.9%
Profit Margin
4.2%
PE Ratio
10.6
PS Ratio
0.4
PB Ratio
0.7
EV/EBITDA
5.6
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Chan-Ho Lee open_in_new
Employees
42
Founded
2000
Website
genebiotech.co.kr open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
-2.4% -1.4% -6.1% 11% 19% 39%

News

Loading...

Markets

Exchange Ticker Price
Korea Exchange
MIC: XKRX
PRIMARY
086060
(주)진바이오텍
ISIN: KR7086060001
Shares Out.:
8.611M1 Shares Float: 8.611M2
TV:
SA:
YF:
GF:
BA:
MS:
4,665 KRW
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About GeneBioTech Co. ,Ltd

GeneBioTech Co. ,Ltd, together with its subsidiaries, engages in the manufacture and sale of feed additives and functional food in South Korea. It also manufactures and sells animal drugs. The company was founded in 2000 and is headquartered in Gongju-si, South Korea.

Similar Companies

Industry: Biotechnology (South Korea)
Name
Market Cap diff.
PE
$44.84B
68.19T KRW
170K%
35.5
068270
$28.11B
42.76T KRW
106K%
43.8
196170
$13.37B
20.33T KRW
51K%
146.6
028300
$5.51B
8.37T KRW
21K%
-
087010
$3.99B
6.07T KRW
15K%
-
$2.25B
3.42T KRW
8K%
-
Industry: Biotechnology (Global)
Name
Market Cap diff.
PE
AMGN
$182.42B
691K%
23.9
GILD
$159.92B
605K%
19.0
ARGX
$47.84B
41.39B EUR
181K%
39.9
CSL
$42.36B
60.27B AUD
160K%
29.3
LONN
$42.3B
33.71B CHF
160K%
37.2
NTRA
$27.6B
104K%
-
chevron_leftBack